Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OLN324
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : ARCH Ventures
Deal Size : $100.0 million
Deal Type : Financing
Ollin Launches with Mission to Accelerate Best-in-class Therapies in Ophthalmology
Details : Ollin’s lead clinical-stage program, OLN324, is a higher potency, higher molar dose VEGF/Ang2 bispecific antibody in Phase 1b for patients with either wAMD or DME.
Product Name : OLN324
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
September 17, 2025
Lead Product(s) : OLN324
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : ARCH Ventures
Deal Size : $100.0 million
Deal Type : Financing
Reset All
